Gout Disease: Stages, Complications and Long-Term Care
Updated
Gout disease is a lifelong condition in which too much uric acid (urate) in the blood forms needle-shaped crystals in and around the joints, and sometimes under the skin and in the kidneys. The painful flares are the part people notice, but the crystals stay between attacks and keep building up for as long as the urate level stays high. In most people the cause is that the kidneys and gut remove too little urate, a trait strongly shaped by genes, rather than the body making too much. Without treatment, gout can move from occasional flares to tophi, lasting joint damage and kidney stones, and it often comes with high blood pressure, kidney disease and heart disease. This guide covers why urate builds up, the stages, the complications, how urate-lowering therapy works, what to expect when starting it and how it is monitored, following the American College of Rheumatology (2020), EULAR (2016) and NICE (2022) guidelines.
- What it isA chronic disease of urate crystal deposits in joints and other tissues
- Main causeKidneys and gut removing too little urate, with genes playing a large part
- Treatment goalSerum urate below 6 mg/dL (360 µmol/L), lower with tophi (EULAR, NICE)
- Long-term medicinesAllopurinol usually first; febuxostat, probenecid or pegloticase in set situations
What is gout disease?
Gout disease is a chronic disease of monosodium urate crystal deposition: when urate in the blood stays above the level at which it can remain dissolved, crystals form in and around joints and in other tissues, as the 2021 Lancet seminar by Dalbeth and colleagues describes. Raised serum urate, called hyperuricemia, is the most important risk factor, and the Merck Manual puts the saturation point at about 6.8 mg/dL (0.4 mmol/L). The immune system reacts to the crystals through the NLRP3 inflammasome, which releases interleukin-1β and sets off the sudden, painful flare. The 2020 American College of Rheumatology (ACR) guideline calls gout the most common form of inflammatory arthritis, affecting about 9.2 million adults in the United States, or 3.9%. Yet high urate alone is not gout: MedlinePlus Genetics notes that only about one in four people with hyperuricemia go on to develop it, and why the others do not is still unclear.
The Lancet seminar stresses that gout shows itself as separate flares but is a chronic disease. Between flares a joint can look and feel normal while the crystals are still there, which is why NICE asks clinicians to explain at diagnosis that the disease progresses without treatment, because high urate keeps forming new crystals. Gout is more common in men, usually starts in middle age in men and after menopause in women, and is rare in younger people, according to the Merck Manual. MedlinePlus Genetics adds that it varies widely by ancestry: about 1% of people with Asian ancestry have gout, 3 to 4% of people with European ancestry, and 6 to 8% of Māori and Indigenous Taiwanese peoples.
Why does uric acid build up in gout?
Uric acid builds up when the body makes more urate than it removes, and in gout the removal side is usually the problem. Urate is a waste product of purines, which come from the body's own cells and from food. The Merck Manual says reduced excretion by the kidneys is by far the most common cause of hyperuricemia, with reduced removal through the gut as the other route, while increased production is rare and a purine-rich diet is generally only a minor contributor. The 2021 Lancet seminar explains that serum urate is set by transporter proteins in the kidney and gut, particularly GLUT9 (from the SLC2A9 gene), URAT1 (SLC22A12) and ABCG2. MedlinePlus Genetics reports that large studies have linked dozens of genes to gout, most of them urate transporters, and that SLC2A9 and ABCG2 matter most: SLC2A9 variants make the kidneys reabsorb more urate, and ABCG2 variants pass less urate into the gut. This is why gout often runs in families.
- Kidney function: chronic kidney disease lowers urate removal, and the Merck Manual notes that worsening kidney function further impairs excretion and speeds up crystal deposition.
- Medicines: thiazide and loop diuretics reduce urate excretion (Merck Manual), and the NHS also lists some blood pressure medicines, such as ACE inhibitors, as raising the chance of gout.
- Alcohol: ethanol speeds up purine breakdown in the liver and produces lactic acid, which blocks urate secretion by the kidney tubules.
- Hormones: estrogen helps the body remove urate, so urate rises after menopause and the risk of gout goes up (MedlinePlus Genetics).
- Weight and insulin: urate production rises with body size in obesity, and high insulin levels in insulin resistance suppress urate excretion (Merck Manual).
- Over-production (rare): fast cell turnover in lymphoma, leukemia, hemolytic anemia or psoriasis, cancer treatment and tumor lysis syndrome, and rare enzyme defects such as Lesch-Nyhan syndrome.
Diet matters less than many people expect. The Merck Manual notes that a strict low-purine diet lowers serum urate by only about 1 mg/dL, so it is rarely enough on its own, and NICE NG219 says there is not enough evidence that any specific diet prevents flares or lowers urate, advising a healthy, balanced diet instead. The ACR guideline still conditionally suggests limiting alcohol, purine-rich foods and high-fructose corn syrup, losing weight when overweight, and it advises against vitamin C supplements for gout.
Medicines are the part of this list you can act on with your doctor, and the advice is spread across several sources: the ACR guideline suggests switching hydrochlorothiazide to another blood pressure medicine when feasible and choosing losartan, which lowers urate, but not stopping aspirin taken for a good reason. AskMed is a medical question app made for doctors, nurses, pharmacists, medical students and researchers. Instead of answering from memory, it searches journals, clinical guidelines and drug labels first, then writes an answer with a link after every claim. Ask it whether one of your regular medicines, such as a diuretic (water pill) or a blood pressure tablet, can raise uric acid and what the gout guidelines say about alternatives, and each point links to the guideline or label it comes from, so you can discuss it with your prescriber rather than change anything on your own.
Ask AskMed whether one of your medicines raises uric acid:
What are the stages of gout disease?
Gout disease is traditionally described in four stages: asymptomatic hyperuricemia, acute flares, intercritical periods between flares, and chronic tophaceous gout. The first stage is a raised urate with no symptoms; most people with high urate stay there, and the ACR 2020 guideline advises against urate-lowering medicine at this stage, because in the trials it reviewed 24 people would need treatment for 3 years to prevent a single flare. The second stage begins with the first flare, which the Merck Manual says usually affects one joint, most often the big toe, and settles over 7 to 10 days. The third stage is the gap between flares, when there are no symptoms: the crystals remain, the gaps tend to get shorter, and MedlinePlus Genetics notes that most people who have more than one flare have their second within a year. In the fourth stage, without urate-lowering therapy, continued crystal deposition causes tophi and a chronic, deforming arthritis.
Later flares tend to involve more joints and, untreated, can last up to 3 weeks, the Merck Manual says, and gout is generally more severe when it starts before age 30 or when the baseline urate is above 9 mg/dL. Imaging has shown that crystals can be present before anyone feels them: an ultrasound "double-contour sign" over cartilage and tophi too small to feel may be visible even before the first flare. To capture this, Dalbeth and Stamp (2014) proposed a staging system built around the crystals themselves: stage A is hyperuricemia without crystals or symptoms, stage B is crystal deposition seen by microscopy or advanced imaging without symptoms, stage C is crystal deposition with past or current flares, and stage D is advanced gout that needs specialist care. Either way, the point is the same: the disease continues between flares.
What complications can gout disease cause?
The complications of gout disease come from crystals building up over years in the joints, under the skin and in the kidneys, and from the conditions that tend to travel with gout. Tophi are lumps of urate crystals; the Merck Manual describes them as firm white or yellow nodules on the fingers, hands, feet, around the elbow or Achilles tendon and on the ears, which are normally painless but can become inflamed, and can break through the skin and discharge chalky material that may become infected. Tophi in and around joints can erode bone and cause deformity and secondary osteoarthritis, and the NHS lists lasting joint damage among the results of untreated chronic gout. In the kidneys, urate can form stones: MedlinePlus Genetics puts this at about 15% of people with gout, and the Merck Manual notes that people with gout may form uric acid or calcium oxalate stones, which can block the flow of urine.
Kidney disease, heart disease and metabolic syndrome
Gout rarely comes alone. MedlinePlus Genetics says most people with gout have high blood pressure, chronic kidney disease or obesity, and some also have diabetes, heart disease or a past stroke, though it is unclear whether gout causes these conditions, they cause gout, or both. The ACR guideline acknowledges links between serum urate and high blood pressure, cardiovascular disease and kidney disease, the CARES trial investigators note that cardiovascular risk is raised in people with gout, and the Merck Manual says the high rate of metabolic syndrome and cardiovascular disease in gout is tied to higher mortality. The kidney link runs both ways: reduced kidney function raises urate, and stones can cause obstruction and infection that damage the kidney further. Lowering urate has not been shown to prevent heart events, though: a meta-analysis of 18 studies and 7,757 people, cited in the 2020 American Family Physician review, found no evidence that urate-lowering therapy reduces cardiovascular risk. That is why NICE suggests checking cardiovascular risk factors and kidney function at follow-up. Kidney function is usually reported as an eGFR, which sets the chronic kidney disease stage that guidelines use in gout decisions; our eGFR calculator shows how it is worked out.
How is gout disease treated long term?
Gout disease is treated long term with urate-lowering therapy (ULT), medicines that keep serum urate below the level at which crystals form, so that existing crystals slowly dissolve and new ones stop forming. The ACR 2020 guideline strongly recommends starting ULT for anyone with one or more tophi, gout damage on X-ray or two or more flares a year, and conditionally for people who have had more than one flare but fewer than two a year. After a first flare it suggests ULT only with chronic kidney disease stage 3 or worse, a serum urate above 9 mg/dL or kidney stones. NICE NG219 is broader: it advises offering ULT for multiple or troublesome flares, chronic kidney disease stages 3 to 5, diuretic use, tophi or chronic gouty arthritis, and discussing it with everyone else after a flare, while EULAR says ULT should be considered from the first presentation. All three use a treat-to-target strategy.
The main medicine classes
- Xanthine oxidase inhibitors (allopurinol, febuxostat): reduce how much urate the body makes. The ACR prefers allopurinol as the first medicine for everyone, including people with chronic kidney disease stage 3 or worse, started low and raised to reach the target; EULAR also puts allopurinol first, adjusted to kidney function; NICE offers either allopurinol or febuxostat first, but allopurinol for people with major cardiovascular disease.
- Febuxostat and the heart: in the CARES trial of 6,190 people with gout and cardiovascular disease, febuxostat was noninferior to allopurinol for major cardiovascular events, but death from any cause (hazard ratio 1.22) and cardiovascular death (1.34) were higher. The ACR suggests switching to another medicine after a cardiovascular event or with a history of cardiovascular disease.
- Uricosurics (probenecid): help the kidneys pass more urate. The Merck Manual says they suit people who under-excrete urate, have normal kidney function and no kidney stones; the ACR prefers a xanthine oxidase inhibitor over probenecid in chronic kidney disease stage 3 or worse; EULAR suggests a uricosuric alone or added to a xanthine oxidase inhibitor when the target is not reached.
- Pegloticase: a uricase enzyme that turns urate into allantoin, which dissolves more easily. The ACR recommends against it as a first medicine, and recommends it for frequent flares or tophi that are not resolving once other treatments have failed to reach the target; EULAR reserves it for refractory gout.
Two safety points come before allopurinol. The ACR conditionally recommends testing for the HLA-B*5801 gene variant in people of Southeast Asian descent, such as Han Chinese, Korean or Thai, and in African American people, because carriers have a higher risk of a severe allopurinol hypersensitivity reaction. And the medicines that calm a flare, such as colchicine, NSAIDs and steroids, do not lower urate, so the Merck Manual notes they cannot prevent the joint damage caused by tophi.
What should you expect when starting urate-lowering therapy?
When urate-lowering therapy starts, gout flares often become more frequent for a while before they settle, because a falling urate level loosens existing crystals, and knowing this in advance helps people stay on treatment. The Merck Manual notes that flares tend to develop during the first months of urate-lowering therapy and that a sudden fall in serum urate is a common trigger. For that reason the ACR 2020 guideline strongly recommends taking an anti-inflammatory medicine alongside it, such as colchicine, an NSAID or prednisone, for 3 to 6 months rather than less, and NICE offers colchicine while the target is being reached, with an NSAID or a corticosteroid as alternatives. NICE suggests starting urate-lowering therapy 2 to 4 weeks after a flare settles, or during a flare if flares are frequent, and the ACR conditionally supports starting during a flare. The dose starts low and is raised step by step, guided by blood tests, until urate reaches the target.
- Keep going during a flare: the Merck Manual says urate-lowering therapy should not be stopped because of a flare, and the NHS advises taking it regularly even when there are no symptoms.
- Tophi shrink slowly: resolving tophi may take many months even with urate at target, and the lower the urate, the faster they dissolve.
- Usually for life: NICE says treatment usually continues after the target is reached and is typically lifelong, and the ACR conditionally recommends continuing it indefinitely rather than stopping.
- Support helps: the ACR suggests dose management by nurses or other non-physician staff, with education and shared decisions, and the Lancet seminar reports that nurse-led care leads to major improvements in outcomes.
The reward for sticking with it is real: the Lancet seminar says long-term urate-lowering therapy dissolves the crystals, which ultimately prevents flares and tophi and improves quality of life. The early months raise the most questions, such as whether a new flare means the medicine is failing, how long the preventive medicine should last, or what a rash means. Ask AskMed why flares can increase after starting allopurinol and what the ACR and NICE guidelines say about preventing them, and the answer sets out each recommendation with a link to the guideline section it comes from, so you can check the wording and bring focused questions to the clinician who manages your gout.
Ask AskMed about starting urate-lowering therapy:
How is gout disease monitored, and when should you see a doctor?
Gout disease is monitored mainly with the serum urate blood test, checked often while the dose is being adjusted and then at longer intervals once the target is reached. NICE NG219 advises using monthly serum urate levels to guide dose increases until the target is met, then considering an annual check for people who continue treatment, and the Merck Manual describes the same pattern: monthly while the right dose is found, at least yearly afterwards, and more often after medicine changes or weight gain. NICE also suggests a follow-up visit after a flare settles to measure urate, review medicines, discuss long-term treatment and assess cardiovascular risk factors and chronic kidney disease. It suggests referral to a rheumatology service when the diagnosis is uncertain, when treatment is not tolerated or not working, with chronic kidney disease stages 3b to 5, or after an organ transplant. For diagnosis, NICE treats a serum urate of 360 µmol/L (6 mg/dL) or more as confirming gout in someone with typical signs.
See a doctor if you have symptoms of gout for the first time or if your usual treatment is not helping, the NHS advises. It is also worth asking about long-term treatment if flares keep coming back, if you notice lumps on the fingers, elbows or ears, or if you have had kidney stones. Get urgent care for a suddenly painful, swollen joint when the pain is getting worse or you also have a high temperature, feel hot, cold or shivery, or feel sick and cannot eat: the NHS warns this could be an infection inside the joint. If a rash appears after starting allopurinol, contact your doctor straight away, because the Merck Manual notes a rash can be the first sign of a rare but serious reaction. And because NICE says urate-lowering therapy is usually lifelong, talk to your doctor before stopping it, even when you feel well.
Frequently asked questions
Is gout a lifelong disease?
Usually, yes. NICE NG219 describes gout as a lifelong condition that benefits from long-term urate-lowering therapy, which is typically continued for life after the target urate is reached. The ACR 2020 guideline also conditionally recommends continuing treatment indefinitely rather than stopping it.
Can gout disease be cured?
The crystals can be dissolved. Keeping serum urate below target makes existing crystals dissolve over time, which prevents flares and tophi, and EULAR describes reaching the urate target as the way to cure the disease. Because high urate would form new crystals, treatment usually continues long term.
Should high uric acid without symptoms be treated?
Usually not with medicine. The ACR 2020 guideline conditionally recommends against urate-lowering therapy for asymptomatic hyperuricemia, because 24 people would need treatment for 3 years to prevent one flare. Only about one in four people with high urate develop gout, according to MedlinePlus Genetics.
What uric acid level should you aim for with gout?
Below 6 mg/dL (360 µmol/L) in the ACR, EULAR and NICE guidelines. EULAR advises below 5 mg/dL (300 µmol/L) for severe gout, and NICE suggests considering it for tophi, chronic gouty arthritis or ongoing flares. The ACR does not set a lower number.
Can diet alone control gout?
Rarely. The Merck Manual notes that a strict low-purine diet lowers serum urate by only about 1 mg/dL, and NICE says no specific diet has been shown to prevent flares. A healthy, balanced diet, less alcohol and weight loss when overweight are still advised alongside treatment.
Is febuxostat safe with heart disease?
It needs care. In the CARES trial of people with gout and cardiovascular disease, death from any cause and cardiovascular death were higher with febuxostat than allopurinol. NICE offers allopurinol first with major cardiovascular disease, and the ACR suggests switching to another medicine in that situation.
Sources
- FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760.
- Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42.
- National Institute for Health and Care Excellence. Gout: diagnosis and management (NG219). NICE guideline, 9 June 2022.
- Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397:1843-1855.
- Dalbeth N, Stamp L. Hyperuricaemia and gout: time for a new staging system? Ann Rheum Dis. 2014;73:1598-1600.
- White WB, Saag KG, Becker MA, et al.; CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200-1210.
- Clebak KT, Morrison A, Croad JR. Gout: Rapid Evidence Review. Am Fam Physician. 2020;102(9):533-538.
- MedlinePlus Genetics. Gout. National Library of Medicine, last updated 1 August 2018.
- Keller SF. Gout. Merck Manual Professional Version, reviewed July 2025.
- NHS. Gout. Last reviewed 24 August 2023.
